- Company
- Protein C deficiency drug 'Ceprotin' begins negotiations
- by Eo, Yun-Ho Jul 12, 2024 05:48am
- 'Ceprotin' has entered the last stage of obtaininig reimbursement listing. According to our investigation, Takeda Pharmaceuticals Korea has started to negotiate drug pricing with the National Health Insurance Service (NHIS) for Ceprotin (Human potein C), a novel drug for the treatment of congenital protein C deficiency. ‘Human protei
- Company
- Will Epkinly become a game-changer in the blood cancer mkt?
- by Hwang, Byung-woo Jul 12, 2024 05:47am
- The arrival of bispecific antibody-based therapies in Korea is expected to shift the blood cancer treatment market paradigm. The industry is welcoming the introduction of a new treatment option, as an unmet need exists in diffuse large B-cell lymphoma (DLBCL), which has a poor prognosis even after three or later lines of treatments. Ab
- Company
- "Enhertu gets expanded indication to treat lung cancer"
- by Son, Hyung-Min Jul 11, 2024 06:12am
- “Previously, patients could only use Enhertu by participating in clinical trials conducted in tertiary general hospitals. Current approval in South Korea will provide a new treatment option for patients with HER2 mutant metastatic non-small cell lung cancer (NSCLC). Brain metastasis is common in lung cancer patients. Because Enhertu demonst
- Company
- Will Trodelvy be deliberated for reimb by DREC in August?
- by Eo, Yun-Ho Jul 11, 2024 05:47am
- The road to reimbursement for the new ADC breast cancer drug Troldelvy remains a bumpy one. The agenda remains pending for 8 months now. Gilead Sciences' triple-negative breast cancer (TNBC) drug Troldelvy, whose reimbursement request received 100,000 consents in a public petition, was not presented for deliberation to the Health Insuranc
- Company
- From obesity to brain diseases...expansion of GLP-1 agonists
- by Son, Hyung-Min Jul 11, 2024 05:46am
- The domestic pharmaceutical bio industry is looking into the possibility of developing various new drugs with GLP-1 agents. As Novo Nordisk and Lilly's GLP-1-based obesity drugs have become global blockbusters, latecomers are also avidly developing jumping in to develop the next blockbuster. Major domestic companies are conducting clinical s
- Company
- GC Biopharma ships first batch of ‘Alyglo’ to the U.S.
- by Son, Hyung-Min Jul 10, 2024 05:48am
- GC Biopharma announced on the 8th that it has completed the shipment of the first batch of its blood product ‘Alyglo’, which was approved by the U.S. Food and Drug Administration (FDA) late last year. The shipment will be delivered to specialized pharmacies through warehouses and distributors in the U.S. and is expected to be available f
- Company
- Tecentriq reapplies for reimb in early stage NSCLC
- by Eo, Yun-Ho Jul 10, 2024 05:48am
- The immuno-oncology drug Tecentriq is reattempting to expand insurance reimbursement to early-stage lung cancer. According to Dailypharm coverage, Roche Korea's PD-L1 inhibitor Tecentriq (atezolizumab) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (July 10). The s
- Company
- With Lixiana and Enhertu, Daiichi-Sankyo’s sales growth↑
- by Hwang, Byung-woo Jul 9, 2024 06:07am
- Daiichi-Sankyo Korea has achieved continuous sales growth over the past five years with Enhertu (ingredient: trastuzumab deruxtecan) and Lixiana (ingredient: edoxaban). Last year, it recorded sales of KRW 274 billion, nearing sales of KRW 300 billion. Its operating benefit also topped its peak over the past five years. Japan-based pharmac
- Company
- Industry struggles to develop new atopic dermatitis drugs
- by Son, Hyung-Min Jul 9, 2024 05:51am
- The domestic pharmaceutical bio-industry is facing difficulties in developing new drugs for atopic dermatitis. Recently, Kangstem Biotech's stem cell therapy drug completed Phase III clinical trials, but the results fell short of expectations. JW Pharmaceutical's atopic dermatitis drug candidate failed to prove its efficacy in a Phase II clinica
- Company
- Takeda seeks top-line growth to KRW 300 billion
- by Hwang, Byung-woo Jul 9, 2024 05:51am
- Takeda Pharmaceuticals Korea achieved a double win last year, seeing improvements in sales and operating income. In particular, thanks to the growth of its anti-cancer drug portfolio, the company's sales exceeded the KRW 250 billion mark for the first time in 3 years since 2020, increasing sales growth for the second consecutive year. i
